Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PRAMIPEXOLE DIHYDROCHLORIDE
- A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
- Long-term Efficacy of Pramipexole in Anhedonic Depression
- Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)
- Pramipexole for Anhedonic Depression
- Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
- Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression
- Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
- Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets
- Social Decision Making in Parkinson's Disease
- Pramipexole and Morphine for Renal Colic
- Pramipexole to Target "Anhedonic Depression"
- the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
- A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
- Non-Opioid Pramipexole and Pain
- Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients
- Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD
- Pramipexole and Emotional Processing
- A Study in Patients With Major Depressive Disorder
- The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
- a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
- Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg
- Targeting Cognition in Bipolar Disorder With Pramipexole
- L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease
- Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers
- Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers
- Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers
- Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers
- In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers
- Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
- Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease
- Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
- Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
- Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
- Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
- The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia
- Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
- Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
- Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
- Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
- Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients
- Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
- Imaging Dopamine Release in Depression
- Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
- Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
- A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease
- A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
- Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
- Pramipexole as a Treatment for Cocaine Dependence
- The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
- Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
- Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression
- Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease
- a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
- Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
- Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers
- Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
- Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers
- Pramipexole for Binge Eating Disorder
- Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
- Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions
- Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions
- Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
- Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease
- Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists
- Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance
- Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily
- A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
- Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
- Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
- Pramipexole ER vs. Placebo in Fibromyalgia
- Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
- Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
- Neuroma Injections to Treat Restless Legs Syndrome - RCT
- Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)
- Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
- Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
- R(+)PPX High Dose Treatment of ALS
- Cognitive Enhancement in Bipolar Disorder
- Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
- Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
- A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
- Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
- Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
- Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
- Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)
- Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors
- Pivotal Study in Advanced Parkinsons Disease Patients
- Impact of Switching to Continuous Release Dopamine Agonists
- A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
- A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.
- A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
- Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances
- A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
- Profile of Depressive Symptoms in Parkinsons Disease
- SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
- SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
- Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
- Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease
- Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
- Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
- Pramipexole Conversion to Ropinirole Controlled Release (CR)
- Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
- Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
- A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease
- Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
- Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
- Effectiveness of Pramipexole for Treatment-Resistant Depression
- Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome
- Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome
- A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)
- Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
- Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
- R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
- Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
- Neuromodulation and Language Acquisition (Stage Ib)
- Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
- Lexapro and Pramipexole and to Treat Major Depression
- ACP-103 to Treat Parkinson's Disease
- Clinical Trial of Pramipexole in Bipolar Depression
Clinical trials list
click for details